Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)

• Company Description    MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland. Number of Employees: 91

• Price / Volume Information    Yesterday's Closing Price: $1.27 Daily Weekly Monthly 20 Day Moving Average: 760,188 shares Shares Outstanding: 103.21 (millions) Market Capitalization: $131.59 (millions) Beta: 1.52 52 Week High: $1.87 52 Week Low: $0.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.82% 3.56% 12 Week 11.84% 9.48% Year To Date -17.74% -26.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9713 Key West Avenue Suite 400 - ROCKVILLE,MD 20850 USA ph: 301-944-1700 fax: 301-944-1703 ir@maxcyte.com http://www.maxcyte.com

• General Corporate Information    Officers Maher Masoud - Chief Executive Officer and President Richard Douglas - Chairman Douglas Swirsky - Chief Financial Officer Yasir Al-Wakeel - Director Will Brooke - Director Peer Information MaxCyte, Inc. (CORR.) MaxCyte, Inc. (RSPI) MaxCyte, Inc. (CGXP) MaxCyte, Inc. (BGEN) MaxCyte, Inc. (GTBP) MaxCyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 57777K106 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 103.21 Most Recent Split Date: (:1) Beta: 1.52 Market Capitalization: $131.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.25 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.86 Price/Cash Flow: - Price / Sales: 4.24 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: -14.53% vs. Previous Quarter: -24.66% ROE 06/30/26 - -18.92 03/31/26 - -20.03 12/31/25 - -22.15 ROA 06/30/26 - -16.14 03/31/26 - -17.14 12/31/25 - -18.98 Current Ratio 06/30/26 - 12.26 03/31/26 - 12.04 12/31/25 - 8.30 Quick Ratio 06/30/26 - 11.47 03/31/26 - 11.29 12/31/25 - 7.77 Operating Margin 06/30/26 - -103.32 03/31/26 - -110.15 12/31/25 - -124.38 Net Margin 06/30/26 - -114.77 03/31/26 - -121.16 12/31/25 - -135.14 Pre-Tax Margin 06/30/26 - -114.77 03/31/26 - -121.16 12/31/25 - -135.14 Book Value 06/30/26 - 1.48 03/31/26 - 1.57 12/31/25 - 1.61 Inventory Turnover 06/30/26 - 0.84 03/31/26 - 0.82 12/31/25 - 0.79 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©